Why the study?
Do DNA aptamers A9 and B4 inhibit H9N2 avian influenza virus infection in MDCK cells?
Do DNA aptamers A9 and B4 inhibit H9N2 avian influenza virus infection in MDCK cells?
DNA aptamers A9 and B4 demonstrate binding affinity and inhibitory effects against H9N2 avian influenza virus in vitro, providing a foundation for future anti-influenza drug development.
May guide aptamer-based antiviral development; leaves open in vivo efficacy and clinical translation.
New antiviral therapy for pandemic influenza mediated by the H9N2 avian influenza virus (AIV) is increasingly in demand not only for the poultry industry but also for public health. Aptamers are confirmed to be promising candidates for treatment and prevention of influenza viral infections. Thus, we studied two DNA aptamers, A9 and B4, selected by capillary electrophoresis-based systemic evolution of ligands by exponential enrichment (CE-SELEX) procedure using H9N2 AIV purified haemagglutinin (HA) as target. Both aptamers had whole-virus binding affinity. Also, an enzyme-linked aptamer assay (ELAA) confirmed binding affinity and specificity against other AIV subtypes. Finally, we studied aptamer-inhibitory effects on H9N2 AIV infection in Madin-Darby canine kidney (MDCK) cells and quantified viral load in supernatant and in cell with quantitative PCR (qPCR). Our data provide a foundation for future development of innovative anti-influenza drugs.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: